Bryan Giraudo Biography and Net Worth

Mr. Giraudo has served on our board of directors since May 2018. He has served as both Chief Financial Officer and Chief Operating Officer of Gossamer Bio, Inc. (Nasdaq: GOSS), a biotechnology company, since September 2021, and as Gossamer’s Chief Financial Officer since May 2018. Prior to joining Gossamer Bio, Mr. Giraudo was a Senior Managing Director at Leerink Partners from 2009 to April 2018, where he was responsible for their western North America and Asia Pacific biotechnology and medical technology banking practice. Before joining Leerink, he was a Managing Director with Merrill Lynch and Co.’s Global Healthcare Investment Banking Group. Mr. Giraudo joined Merrill Lynch in 1997. As a banker, he completed over 200 corporate finance, corporate partnership and strategic advisory transactions. Mr. Giraudo has been a member of the board of directors of Valerio Therapeutics, S.A. (EPA: ALVIO), a biotechnology company, since November 2021. He received a B.A. from Georgetown University.

What is Bryan Giraudo's net worth?: The estimated net worth of Bryan Giraudo is at least $590.41 thousand as of May 7th, 2026. Giraudo owns 6,000 shares of Protagonist Therapeutics stock worth more than $590,406 as of May 12th. This net worth estimate does not reflect any other assets that Giraudo may own. Learn More about Bryan Giraudo's net worth.
How do I contact Bryan Giraudo?: The corporate mailing address for Giraudo and other Protagonist Therapeutics executives is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. Protagonist Therapeutics can also be reached via phone at (510) 474-0170 and via email at [email protected]. Learn More on Bryan Giraudo's contact information.
Has Bryan Giraudo been buying or selling shares of Protagonist Therapeutics?: During the past quarter, Bryan Giraudo has sold $5,918,880.00 of Protagonist Therapeutics stock. Most recently, Bryan Giraudo sold 5,130 shares of the business's stock in a transaction on Friday, May 8th. The shares were sold at an average price of $100.00, for a transaction totalling $513,000.00. Following the completion of the sale, the director now directly owns 12,695 shares of the company's stock, valued at $1,269,500. Learn More on Bryan Giraudo's trading history.
Who are Protagonist Therapeutics' active insiders?: Protagonist Therapeutics' insider roster includes Asif Ali (EVP, CFO), Bryan Giraudo (Director), Suneel Gupta (Chief Development Officer), David Liu (Insider), Arturo Molina (Chief Medical Officer), Dinsesh Patel (CEO), Harold Selick (Director), William Waddill (Director), and Lewis Williams (Director). Learn More on Protagonist Therapeutics' active insiders.
Are insiders buying or selling shares of Protagonist Therapeutics?: In the last year, insiders at the sold shares 29 times. They sold a total of 475,371 shares worth more than $40,685,023.07. The most recent insider tranaction occured on May, 8th when Director Bryan Giraudo sold 5,130 shares worth more than $513,000.00. Insiders at Protagonist Therapeutics own 5.2% of the company. Learn More about insider trades at Protagonist Therapeutics.
Information on this page was last updated on 5/8/2026.

Bryan Giraudo Insider Trading History at Protagonist Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/8/2026	Sell	5,130	$100.00	$513,000.00	12,695
5/8/2026	Sell	6,000	$100.00	$600,000.00	31,825
5/7/2026	Sell	36,000	$100.14	$3,605,040.00	27,825
5/7/2026	Sell	12,000	$100.07	$1,200,840.00	6,000
12/3/2019	Buy	8,000	$5.70	$45,600.00	10,000
5/16/2018	Buy	10,000	$6.46	$64,600.00	10,000

Bryan Giraudo Buying and Selling Activity at Protagonist Therapeutics

Protagonist Therapeutics Company Overview

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Today's Range

Now: $99.95

$98.36

$103.66

50 Day Range

MA: $99.95

$91.30

$105.98

2 Week Range

Now: $99.95

$43.20

$107.84

Volume

645,549 shs

Average Volume

768,389 shs

Market Capitalization

$6.43 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.89